诱导多潜能干细胞的研究进展

宋捷; 缪朝玉

doi:10.3969/j.issn.1006-0111.2012.01.001

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001

宋捷,
缪朝玉

第二军医大学药理学教研室,上海 200433

基金项目: 国家973计划课题(2009CB521902) ; 国家科技重大专项"重大新药创制"(2009ZX09303-002) .

Progress on induced pluripotent stem cell

Department of Pharmacology, Second Military Medical University, Shanghai 200433, China

摘要: 诱导多潜能干细胞(IPSC)自2006年问世,就备受全球各大实验室广泛关注,成为生命科学领域新的里程碑。本篇综述旨在回顾多潜能性的研究历史,重点介绍IPSC培养技术,探讨IPSC培养技术在细胞治疗方面的应用前景。通过大量查阅国内外相关领域的综述及论著,本文归纳总结近年来IPSC领域的最新研究成果,以期为该领域后续的探索性研究提供参考。
- 多潜能性细胞 /
- IPSC培养技术 /
- 细胞治疗
Abstract: The IPSC technology, which was discovered in 2006, had drawn much attention among laboratories around the world and become a new milestone in the life science. The history of pluripotency study, with an emphasis on the culturing technology of IPSC and its potential applications in cell therapy was reviewed. According to the large amount of reviews and articles, the progress that had been made in the IPSC field in recent years in hope to provide some references for the subsequent research.
- pluripotent cell /
- IPSC culturing technology /
- cell therapy

[1]	Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4): 663.
[2]	Briggs R, King TJ. Transplantation of living nuclei from blastula cells into enucleated frogs'eggs[J]. Proc Natl Acad Sci,1952, 38(5): 455.
[3]	Miller RA, Ruddle FH. Pluripotent teratocarcinoma-thymus somatic cell hybrids[J]. Cell,1976,9(1): 45.
[4]	Xie H, Ye M, Feng R, et al. Stepwise reprogramming of B cells into macrophages[J]. Cell,2004, 117(5): 663.
[5]	Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts[J]. Cell,1987, 51(6): 987.
[6]	Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors[J]. Cell,2010, 142(3): 375.
[7]	Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes[J]. Nat Biotechnol,2008, 26(11): 1276.
[8]	Eminli S, Utikal J, Arnold K, et al. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression[J]. Stem Cells,2008, 26(10): 2467.
[9]	Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells[J]. J Cell Sci,2009, 122(Pt 19): 3502.
[10]	Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic β cells into induced pluripotent stem cells[J]. Curr Biol,2008, 18(12): 890.
[11]	Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells[J]. Proc Natl Acad Sci USA, 2009,106(37):15720.
[12]	Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency[J]. Cell,2008, 133(2): 250.
[13]	Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation[J]. Nature,2009, 461(7260): 86.
[14]	Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells[J]. Nature,2007, 448(7151): 313.
[15]	Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration[J]. Science,2008, 322(5903): 945.
[16]	Varas F, Stadtfeld M, de Andres-Aguayo L, et al. Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions[J]. Stem Cells,2009, 27(2): 300.
[17]	Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome[J]. Proc Jpn Acad,2009, 85(8): 348.
[18]	Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences[J]. Science,2009, 324(5928): 797.
[19]	Jia F, Wilson KD, Sun N, et al. A nonviral minicircle vector for deriving human iPS cells[J]. Nat Methods,2010, 7(3): 197.
[20]	Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells[J]. Nature,2009, 458(7239): 766.
[21]	Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins[J]. Cell Stem Cell,2009, 4(5): 381.
[22]	Cho HJ, Lee CS, Kwon YW, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation[J]. Blood,2010, 116(3): 386.
[23]	Desponts C, Ding S. Using small molecules to improve generation of induced pluripotent stem cells from somatic cells[J]. Methods Mol Biol,2010, 636: 207.
[24]	Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells[J]. Cell,2008, 134(5): 877.
[25]	Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient[J]. Nature,2009, 457(7227): 277.
[26]	Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs[J]. Nature,2009,461(7262): 402.
[27]	Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome[J]. Nature,2010,465(7299): 808.
[28]	Hanna J, Wernig M, Markoulaki S, et al.Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin[J]. Science,2007, 318(5858): 1920.
[29]	M. Wernig, J. Pruszak, E. Hedlund, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease[J].Proc Natl Acad Sci,2008,105(15) : 5856.
[30]	D. Xu, LM. Fink, DM. Adcock, et al. Phenotypic correction ofmurine hemophilia A using an iPS cell-based therapy[J]. Proc Natl Acad Sci,2009,106(3) :808.
[31]	T.J. Nelson, S. Yamada, C. Perez-Terzic, et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells[J].Circ,2009,120(5) :408.
[32]	Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells[J]. Nature,2009, 460(7251):53.
[33]	Couzin J. Celebration and concern over U.S. trial of embryonic stem cells[J]. Science,2009,323(5914):568.

[1]	丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉. 消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
[2]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
[3]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
[4]	陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼. 通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
[5]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[6]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[7]	瞿文君, 白若楠, 崔力, 周琰. 基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
[8]	姚小静, 计佩影, 陆峰, 施国荣, 傅翔. 表面增强拉曼光谱法快速测定尿液中曲马多的研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202401072
[9]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[10]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[11]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[12]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
[13]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[14]	陈金涛, 乔子婴, 马明华, 张若曦, 王振伟, 年华. 基于网络药理学和分子对接技术研究金芪清疏颗粒治疗社区获得性肺炎的潜在机制 . 药学实践与服务, 2024, 42(11): 471-478. doi: 10.12206/j.issn.2097-2024.202312014
[15]	修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星. 全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
[16]	姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量. 巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
[17]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[18]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[19]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[20]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044

点击查看大图

计量

文章访问数: 4407
HTML全文浏览量: 267
PDF下载量: 501
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001

Progress on induced pluripotent stem cell

计量

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001

第二军医大学药理学教研室,上海 200433

English Abstract

Progress on induced pluripotent stem cell

Department of Pharmacology, Second Military Medical University, Shanghai 200433, China

全文HTML

目录

留言板

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001

Progress on induced pluripotent stem cell

计量

出版历程

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001

第二军医大学药理学教研室,上海 200433

English Abstract

Progress on induced pluripotent stem cell

Department of Pharmacology, Second Military Medical University, Shanghai 200433, China

全文HTML

目录